As of 2025-11-17, the Fair Value of Calliditas Therapeutics AB (CALTX.ST) is -40.07 SEK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 208.00 SEK, the upside of Calliditas Therapeutics AB is -119.26%.
With the market price of 208.00 SEK and our fair value calculation, Calliditas Therapeutics AB (CALTX.ST) is not a good investment. Investing in CALTX.ST stocks now will result in a potential loss of 119.26%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 5Y Avg | |
| Net income | -32.58 | -433.49 | -500.29 | -412.27 | -466.18 | -368.96 |
| YoY growth | 75.33% | -1,230.63% | -15.41% | 17.59% | -13.08% | -233.24% |
| Market Cap (mil) | 12,467.52 |
| P/E | |
| Forward P/E |
| EPS | -8.01 |
| Avg earnings growth rate | -233.24% |
| TTM earnings | -480.37 |